title: Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial.
abstract: OBJECTIVE
  To study the combination of 5FUDR, recombinant leukocyte interferon (IFN), and doxorubicin in patients with unresectable hepatocellular carcinoma.
  
  
  METHODS
  IFN was administered at a dose of 6 miu/m(2) subcutaneously followed in 2 h by doxorubicin 20 mg/m(2) intravenously. After doxorubicin, 5FUDR was given as a 24-h infusion at a starting dose of 80 mg/kg. The dose of IFN was escalated to three times a week if tolerated. Both doxorubicin and 5FUDR were administered once weekly.
  
  
  RESULTS
  There were 30 patients entered into the study. Among the 30 patients, there were two partial responses (7%) and one patient had stable disease. Toxicity was generally tolerable with fever, and chills, fatigue, and myelosuppression as the most common side effects.
  
  
  CONCLUSIONS
  This chemotherapy combination was generally well tolerated, but has limited activity in unresectable, advanced hepatocellular carcinoma.
authors.affiliation: Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, 1475 NW 12th Avenue, Miami, Florida, USA.
authors.forename: Lynn G
authors.initials: LG
authors.lastname: Feun
authors.forename: Christopher
authors.initials: C
authors.lastname: O'Brien
authors.forename: Enrique
authors.initials: E
authors.lastname: Molina
authors.forename: Miguel
authors.initials: M
authors.lastname: Rodriguez
authors.forename: Lenox
authors.initials: L
authors.lastname: Jeffers
authors.forename: Eugene R
authors.initials: ER
authors.lastname: Schiff
authors.forename: Angela
authors.initials: A
authors.lastname: Marini
authors.forename: Niramol
authors.initials: N
authors.lastname: Savaraj
authors.forename: Bach
authors.initials: B
authors.lastname: Ardalan
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D007372:Interferons / Q000008:administration & dosage; D007962:Leukocytes; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage; D017211:Treatment Failure
chemical_list: D011994:Recombinant Proteins; D005467:Floxuridine; D004317:Doxorubicin; D007372:Interferons